Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Puromycin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPEPPS | P55786 | 12/20 | 0.97 |
| ▸ | ANPEP | P15144 | 10/20 | 0.97 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.97 |
| ▸ | TP53 | P04637 | 2/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.97 |
| ▸ | LMNA | P02545 | 1/20 | 0.97 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.97 |
| ▸ | HTT | P42858 | 1/20 | 0.96 |
| ▸ | NPC1 | O15118 | 1/20 | 0.96 |
| ▸ | RAB9A | P51151 | 1/20 | 0.96 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.96 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Puromycin SCHEMBL14583797 | 0.99 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL3042415 | 0.99 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL21481061 | 0.99 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL14583945 | 0.99 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL22409382 | 0.99 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL24206459 | 0.99 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL22348910 | 0.99 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL20815730 | 0.99 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL21306559 | 0.99 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 | |
| Puromycin SCHEMBL20393806 | 0.99 | NPEPPS (1.00) | NPEPPSANPEPSMN1; SMN2TP53CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| EP-3259597-B2 | PVRIG POLYPEPTIDES AND METHODS OF TREATMENT | COMPUGEN LTD (IL) | 2026-04-15 | — | — | EP | disclosed |
| US-20260069693-A1 | UROLITHINS AND T-CELL MEDIATED IMMUNE RESPONSE | CHEMOTHERAPEUTISCHES FORSCHUNGSINSTITUT GEORG SPEYER HAUS (DE) | 2026-03-12 | — | — | US | disclosed |
| US-20250333503-A1 | ANTI-PVRIG ANTIBODIES AND METHODS OF USE | COMPUGEN LTD (IL) | 2025-10-30 | — | — | US | disclosed |
| EP-4583863-A1 | UROLITHINS AND T-CELL MEDIATED IMMUNE RESPONSE | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus (DE) | 2025-07-16 | — | — | EP | disclosed |
| EP-4561556-A2 | THERAPEUTIC USES OF UROLITHIN DERIVATIVES | Vandria SA (CH) | 2025-06-04 | — | — | EP | disclosed |
| US-12312404-B2 | Anti-PVRIG antibodies and methods of use | COMPUGEN LTD. (IL) | 2025-05-27 | — | — | US | disclosed |
| CN-119947717-A | Therapeutic use of urolithin derivatives | 范徳利亚股份公司 | 2025-05-06 | — | — | CN | disclosed |
| CN-119120588-B | Construction method of KCNB1 ion channel stable transgenic cell strain and application of KCNB1 ion channel stable transgenic cell strain in toxicity screening of plastic movable substances and degradation products | 广州市华代生物科技有限公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-119120384-B | Cell strain stably transferring TRPA1 ion channel, construction method thereof and application thereof in screening of pain caused by immigrants of degradable material | 广州市华代生物科技有限公司 | 2025-02-28 | — | — | CN | disclosed |
| US-20170029504-A1 | ANTI-PVRIG ANTIBODIES AND METHODS OF USE | COMPUGEN LTD. (IL) | 2017-02-02 | — | — | US | disclosed |
| WO-2016134333-A9 | ANTI-PVRIG ANTIBODIES AND METHODS OF USE | COMPUGEN LTD. (IL) | 2017-02-02 | — | — | WO | disclosed |
| WO-2016134335-A9 | PVRIG POLYPEPTIDES AND METHODS OF TREATMENT | COMPUGEN LTD. (IL) | 2016-10-13 | — | — | WO | disclosed |
| WO-2016134333-A1 | ANTI-PVRIG ANTIBODIES AND METHODS OF USE | COMPUGEN LTD. (IL) | 2016-08-25 | — | — | WO | disclosed |
| WO-2016134335-A2 | PVRIG POLYPEPTIDES AND METHODS OF TREATMENT | COMPUGEN LTD. (IL) | 2016-08-25 | — | — | WO | disclosed |
| US-20160244521-A1 | ANTI-PVRIG ANTIBODIES AND METHODS OF USE | COMPUGEN LTD. (IL) | 2016-08-25 | — | — | US | disclosed |
| US-9273364-B2 | Transgenic reporter system that reveals expression profiles and regulation mechanisms of alternative splicing in mammalian organisms | KYOTO UNIVERSITY (JP) | 2016-03-01 | — | — | US | disclosed |
| US-20130137099-A1 | TRANSGENIC REPORTER SYSTEM THAT REVEALS EXPRESSION PROFILES AND REGULATION MECHANISMS OF ALTERNATIVE SPLICING IN MAMMALIAN ORGANISMS | KYOTO UNIVERSITY (JP) | 2013-05-30 | — | — | US | disclosed |
| WO-2012113965-A1 | METHOD FOR OBTAINING DATA THAT CAN BE USED TO EVALUATE, PREDICT AND/OR PROGNOSTICATE RESPONSE TO TREATMENT WITH PYRIMIDINE ANALOGUES | SERVICIO ANDALUZ DE SALUD (ES) | 2012-08-30 | — | — | WO | disclosed |
| WO-2009098451-A2 | BIOMARKERS OF AMINOPEPTIDASE INHIBITION | CHROMA THERAPEUTICS LIMITED (GB) | 2009-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260069693-A1 | UROLITHINS AND T-CELL MEDIATED IMMUNE RESPONSE | MAVS, TFAM, MCU | NPEPPS 4818/4885ANPEP 4531/4885SMN1; SMN2 1243/4885 |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | NPEPPS 3071/4885ANPEP 3374/4885SMN1; SMN2 987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.